Sorafenib Tosylate exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression. These tyrosibne kinases targeted by Sorafenib Tosylate include vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET. Sorafenib Tosylate is a drug used for the treatment of human hepatocellular carcinoma. In clinical use, the effect on HCC by Sorafenib Tosylate is limited. Sorafenib Tosylate is also known as BAY 43-9006, 4-methylbenzenesulfonate, and 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide.
See how others have used Sorafenib Tosylate (CAS 475207-59-1). Click on the entry to view the PubMed entry .
PMID: # 27029796 Thomas, VA. et al. 2016. AAPS J. 18: 923-32.
PMID: # 26070816 Lee, WR. et al. 2015. J Transl Med. 13: 191.
PMID: # 25035930 Nam, KW. et al. 2014. Biochem. Biophys. Res. Commun. 450: 1518-24.
PMID: # 32713860 J. Biosci.
PMID: # 29983874 Oncotarget. 28474-28485.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.